Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trialMathias Rummel, Juergen Barth, Ulrich von Gruenhagen et al.|The Lancet Oncology|2015Cited by 155
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.Mathias Rummel, Wolfram Brugger, Georg Maschmeyer et al.|Journal of Clinical Oncology|2017Cited by 83
Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 StudyMathias Rummel, Wolfram Brugger, Georg Maschmeyer et al.|Blood|2014Cited by 13
Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214)Mathias Rummel, Wolfram Brugger, Andreas Viardot et al.|Blood|2014Cited by 7
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)Mathias Rummel, Wolfram Brugger, Christina Balser et al.|Blood|2014Cited by 5